TMEM106B Polyclonal antibody

TMEM106B Polyclonal Antibody for IF, IHC, IP, WB,ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human, mouse

Applications

WB, IP, IHC, IF,ELISA

Conjugate

Unconjugated

Cat no : 20995-1-AP

Synonyms

TMEM106B, transmembrane protein 106B



Tested Applications

Positive WB detected inA549 cells, mouse brain tissue, human placenta tissue
Positive IP detected inmouse brain tissue
Positive IHC detected inhuman brain tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
Positive IF detected inHeLa cells

Recommended dilution

ApplicationDilution
Western Blot (WB)WB : 1:500-1:2000
Immunoprecipitation (IP)IP : 0.5-4.0 ug for IP and 1:500-1:2000 for WB
Immunohistochemistry (IHC)IHC : 1:20-1:200
Immunofluorescence (IF)IF : 1:20-1:200
Sample-dependent, check data in validation data gallery

Product Information

The immunogen of 20995-1-AP is TMEM106B Fusion Protein expressed in E. coli.

Tested Reactivity human, mouse
Cited Reactivity human, mouse
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen TMEM106B fusion protein Ag14264
Full Name transmembrane protein 106B
Calculated molecular weight 31 kDa
Observed molecular weight 31-35 kDa, 40-55 kDa
GenBank accession numberBC033901
Gene symbol TMEM106B
Gene ID (NCBI) 54664
Conjugate Unconjugated
Form Liquid
Purification Method Antigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

Background Information

TMEM106B is a genetic risk factor for frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP). Amyotrophic lateral sclerosis (ALS), like FTLD-TDP, is characterized by pathological TDP-43 inclusions. TMEM106B expression in the brain may be linked to mechanisms of disease in FTLD-TDP and risk alleles confer genetic susceptibility by increasing gene expression. TMEM106B can be showed as 31-55 kDa and 70-90 kDa (Glycosylated or Dimer) form in western blot test. (PMID: 27543298, 22895706, PMID: 23136129).

Protocols

Product Specific Protocols
WB protocol for TMEM106B antibody 20995-1-APDownload protocol
IHC protocol for TMEM106B antibody 20995-1-APDownload protocol
IF protocol for TMEM106B antibody 20995-1-APDownload protocol
IP protocol for TMEM106B antibody 20995-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
mouseIF

Mol Brain

TMEM106B, a frontotemporal lobar dementia (FTLD) modifier, associates with FTD-3-linked CHMP2B, a complex of ESCRT-III.

Authors - Mi-Hee Jun
humanWB

Alzheimers Res Ther

TMEM106B expression is reduced in Alzheimer's disease brains.

Authors - Jun-Ichi Satoh
humanWB

J Neurosci

TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways.

Authors - Chen-Plotkin Alice S AS